{"id":411612,"date":"2021-01-11T06:03:44","date_gmt":"2021-01-11T11:03:44","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=411612"},"modified":"2021-01-11T06:03:44","modified_gmt":"2021-01-11T11:03:44","slug":"gilead-sciences-announces-updated-2020-guidance","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-sciences-announces-updated-2020-guidance\/","title":{"rendered":"Gilead Sciences Announces Updated 2020 Guidance"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwalignr { text-align: right; list-style-position: inside }\n.bwblockalignl { margin-left: 0px; margin-right: auto }\n.bwcellpmargin { margin-bottom: 0px; margin-top: 0px }\n.bwdoublebottom { border-bottom: double black 2.25pt }\n.bwlistdisc { list-style-type: disc }\n.bwpadl0 { padding-left: 0px }\n.bwpadl3 { padding-left: 15px }\n.bwpadr0 { padding-right: 0px }\n.bwrowaltcolor0 { background-color: #cceeff }\n.bwsinglebottom { border-bottom: solid black 1pt }\n.bwtablemarginb { margin-bottom: 10px }\n.bwuline { text-decoration: underline }\n.bwvertalignb { vertical-align: bottom }\n.bwvertalignt { vertical-align: top }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Gilead Sciences Announces Updated 2020 Guidance<\/b><\/p>\n<p>FOSTER CITY, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nGilead Sciences, Inc. (Nasdaq: GILD) today announced the company has revised certain elements of its full year 2020 guidance.\n<\/p>\n<p><b><span class=\"bwuline\">Updated Full Year 2020 Guidance<\/span><\/b><\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwsinglebottom bwpadl0 bwvertalignb\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><b>(In millions, except percentages and per share amounts)<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwalignc\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\"><b>Previously Updated<br \/>\n<br \/>October 28, 2020<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwalignc\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\"><b>Updated<br \/>\n<br \/>January 11, 2021<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nProduct Sales\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwalignc bwvertalignb\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n$23,000 &#8211; $23,500\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwalignc bwvertalignb\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n$24,300 &#8211; $24,350\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3 bwvertalignb\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nProduct Sales excluding Veklury\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwalignc bwvertalignb\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwalignc bwvertalignb\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n$21,500 &#8211; $21,525\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3 bwvertalignb\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nVeklury\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwalignc bwvertalignb\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwalignc bwvertalignb\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n$2,800 &#8211; $2,825\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nNon-GAAP\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwalignc bwvertalignb\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwalignc bwvertalignb\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3 bwvertalignb\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nProduct Gross Margin\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwalignc bwvertalignb\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n86% &#8211; 87%\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwalignc bwvertalignb\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n~ 86.5%\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3 bwvertalignb\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nR&amp;D Expenses\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwalignc bwvertalignb\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\nMid-teens percentage growth\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwalignc bwvertalignb\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n\u00a0\n<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n~ 20% growth\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3 bwvertalignb\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nSG&amp;A Expenses\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwalignc bwvertalignb\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\nLow double-digit percentage growth\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwalignc bwvertalignb\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n\u00a0\n<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n~ 10% growth\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3 bwvertalignb\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nOperating Income\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwalignc bwvertalignb\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n$10,700 &#8211; $11,200\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwalignc bwvertalignb\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n$11,650 &#8211; $11,750\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3 bwvertalignb\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nEffective Tax Rate\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwalignc bwvertalignb\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n~ 20%\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwalignc bwvertalignb\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n~ 19.0% &#8211; 19.5%\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3 bwvertalignb\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nDiluted EPS\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwalignc bwvertalignb\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n$6.25 &#8211; $6.60\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwalignc bwvertalignb\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n$6.98 &#8211; $7.08\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nGAAP Diluted Earnings (Loss) Per Share\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwalignc bwvertalignb\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n$(0.25) &#8211; $0.10\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwalignc bwvertalignb\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n$(0.08) &#8211; $0.02\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\nThe following provides additional details on the company\u2019s updated guidance:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nGilead delivered solid performance, despite the global impacts of COVID-19.\n<\/li>\n<li>\nTotal product sales guidance range is now $24.30 billion to $24.35 billion, reflecting increased Veklury<sup>\u00ae<\/sup> (remdesivir) sales as hospitalization and treatment rates were higher than expected given the most recent COVID-19 surge.\n<\/li>\n<li>\nAs a reminder, full year 2020 total product sales excluding Veklury reflects the underlying strong Biktarvy<sup>\u00ae<\/sup> (bictegravir 50 mg\/emtricitabine 200 mg\/tenofovir alafenamide 25 mg) uptake, partially offset by the Truvada<sup>\u00ae<\/sup> (emtricitabine 200 mg\/tenofovir disoproxil fumarate 300 mg) loss of exclusivity in the United States and the impact of COVID-19 primarily on Gilead\u2019s pre-exposure prophylaxis (\u201cPrEP\u201d) franchise and chronic hepatitis C virus (\u201cHCV\u201d) franchise.\n<\/li>\n<li>\nGuidance for Research and development (\u201cR&amp;D\u201d) expense changed to reflect the increase in expense for obligations under the previously disclosed new commercialization and development agreement for Jyseleca<sup>\u00ae<\/sup> (filgotinib) with Galapagos NV. In addition, R&amp;D expense for the full year 2020 reflects growth due to higher clinical trial and manufacturing ramp-up expenses related to Gilead\u2019s COVID-19 treatment remdesivir.\n<\/li>\n<li>\nSelling, general and administrative (\u201cSG&amp;A\u201d) expense reflects the low-end of Gilead\u2019s previous guidance. As a reminder, SG&amp;A expense grew for the full year 2020 due to a legal accrual related to a previously disclosed legal settlement, expenses associated with the acquisitions of Forty Seven, Inc. and Immunomedics, Inc., and certain remdesivir donations.\n<\/li>\n<li>\nGAAP Diluted EPS guidance is ($0.08) to $0.02 and Non-GAAP Diluted EPS guidance is $6.98 to $7.08 for full year 2020.\n<\/li>\n<\/ul>\n<p>\nThe updated 2020 guidance range provided in this document is based on Gilead\u2019s preliminary fourth quarter 2020 results, which are subject to change in connection with the completion of the company\u2019s final closing procedures, final adjustments and other developments that may arise in the course of the preparation or audit of its financial statements. Gilead\u2019s management will host a conference call to discuss the company\u2019s fourth quarter and full year 2020 results in the coming weeks.\n<\/p>\n<p><b>Webcast of J.P. Morgan Healthcare Conference<\/b><\/p>\n<p>\nGilead is scheduled to provide an overview of the company, including updated full year 2020 guidance and a review of key events at the 39<sup>th<\/sup> Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 12:40 p.m. Pacific Time. The live webcast for the J.P. Morgan Healthcare Conference can be accessed at the company\u2019s Investors <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Finvestors.gilead.com%2F&amp;esheet=52359306&amp;newsitemid=20210111005378&amp;lan=en-US&amp;anchor=page+at+http%3A%2F%2Finvestors.gilead.com.&amp;index=1&amp;md5=b9828c44223cfd2102c0e86e7e3f0ff9\">page at http:\/\/investors.gilead.com.<\/a><\/p>\n<p><b>Non-GAAP Financial Information<\/b><\/p>\n<p>\nThe information presented in this document has been prepared in accordance with U.S. generally accepted accounting principles (\u201cGAAP\u201d), unless otherwise noted as non-GAAP. Management believes non-GAAP information is useful for investors, when considered in conjunction with Gilead\u2019s GAAP financial information, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Gilead\u2019s operating results as reported under GAAP. Non-GAAP financial information excludes acquisition-related expenses including amortization, acquired in-process research and development (\u201cIPR&amp;D\u201d) expenses including the initial costs of externally developed IPR&amp;D with no alternative future use, upfront collaboration and licensing expenses and IPR&amp;D impairments, and other items that are considered unusual or not representative of underlying trends of Gilead\u2019s business, fair value adjustments of equity securities and discrete and related tax charges or benefits associated with changes in tax related laws and guidelines. Although Gilead consistently excludes the amortization of acquired intangible assets from the non-GAAP financial information, management believes that it is important for investors to understand that such intangible assets were recorded as part of acquisitions and contribute to ongoing revenue generation. Non-GAAP measures may be defined and calculated differently by other companies in the same industry. Reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures are provided in the table on page 4.\n<\/p>\n<p><b>About Gilead Sciences<\/b><\/p>\n<p>\nGilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.\n<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nStatements included in this press release that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward- looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include: the risks and uncertainties related to the impact of the COVID-19 pandemic on Gilead\u2019s business, financial condition and results of operations; the risks and uncertainties related to the development, manufacturing and distribution of Veklury as a treatment for COVID-19, including the uncertainty of the amount and timing of future Veklury revenues and the risk that Gilead may be unable to recoup the expenses incurred to date and future expenses related to the development and production of Veklury and Gilead may be unable to effectively manage the global supply and distribution of Veklury; Gilead\u2019s ability to achieve its anticipated full year 2020 financial results, including as a result of potential adverse revenue impacts from COVID-19, increases in R&amp;D expenses and potential revenues from Veklury; Gilead\u2019s ability to make progress on any of its long-term ambitions laid out in its corporate strategy; Gilead\u2019s ability to accelerate or sustain revenues for its antiviral and other programs; Gilead\u2019s ability to realize the potential benefits of acquisitions, collaborations or licensing arrangements; the ability of the parties to complete the MYR GmbH acquisition in a timely manner or at all; Gilead\u2019s ability to initiate, progress or complete clinical trials within currently anticipated timeframes; the possibility of unfavorable results from ongoing and additional clinical trials; the risk that safety and efficacy data from clinical studies may not warrant further development of Gilead\u2019s product candidates or the product candidates of Gilead\u2019s strategic partners; Gilead\u2019s ability to submit new drug applications for new product candidates in the currently anticipated timelines; Gilead\u2019s ability to receive regulatory approvals in a timely manner or at all, and the risk that any such approval may be subject to significant limitations on use; Gilead\u2019s ability to successfully commercialize its products; the risk of potential disruptions to the manufacturing and supply chain of Gilead\u2019s products; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products; the risk that efforts to control prescription drug prices could have a material adverse effect on Gilead\u2019s business; a larger than anticipated shift in payer mix to more highly discounted payer segments; market share and price erosion caused by the introduction of generic versions of Gilead products; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; and other risks identified from time to time in Gilead\u2019s reports filed with the U.S. Securities and Exchange Commission (the \u201cSEC\u201d). In addition, Gilead makes estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. Gilead bases its estimates on historical experience and on various other market specific and other relevant assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. These forward-looking statements should also be considered in light of various important factors, including, but not limited to, the following: completion of Gilead\u2019s final closing procedures, final adjustments and other developments that may arise in the course of audit procedures. There may be other factors of which Gilead is not currently aware that may affect matters discussed in the forward-looking statements and may also cause actual results to differ significantly from these estimates. Information about these and other risks, uncertainties and factors can be found in Gilead\u2019s periodic reports filed with the SEC, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. Gilead claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements.\n<\/p>\n<p>\nAll forward-looking statements are based on information currently available to Gilead and Gilead assumes no obligation to update or supplement any such forward-looking statements other than as required by law. Any forward-looking statements speak only as of the date hereof or as of the dates indicated in the statements.\n<\/p>\n<p class=\"bwalignc\">\nGilead owns or has rights to various trademarks, copyrights and trade names used in its business, including the following: GILEAD<sup>\u00ae<\/sup>, GILEAD SCIENCES<sup>\u00ae<\/sup>, AMBISOME<sup>\u00ae<\/sup>, ATRIPLA<sup>\u00ae<\/sup>, BIKTARVY<sup>\u00ae<\/sup>, CAYSTON<sup>\u00ae<\/sup>, COMPLERA<sup>\u00ae<\/sup>, DESCOVY<sup>\u00ae<\/sup>, DESCOVY FOR PREP<sup>\u00ae<\/sup>, EMTRIVA<sup>\u00ae<\/sup>, EPCLUSA<sup>\u00ae<\/sup>, EVIPLERA<sup>\u00ae<\/sup>, GENVOYA<sup>\u00ae<\/sup>, HARVONI<sup>\u00ae<\/sup>, HEPSERA<sup>\u00ae<\/sup>, JYSELECA<sup>\u00ae<\/sup>, LETAIRIS<sup>\u00ae<\/sup>, ODEFSEY<sup>\u00ae<\/sup>, RANEXA<sup>\u00ae<\/sup>, SOVALDI<sup>\u00ae<\/sup>, STRIBILD<sup>\u00ae<\/sup>, TECARTUS<sup>TM<\/sup>, TRODELVY<sup>\u00ae<\/sup>, TRUVADA<sup>\u00ae<\/sup>, TRUVADA FOR PREP<sup>\u00ae<\/sup>, TYBOST<sup>\u00ae<\/sup>, VEKLURY<sup>\u00ae<\/sup>, VEMLIDY<sup>\u00ae<\/sup>, VIREAD<sup>\u00ae<\/sup>, VOSEVI<sup>\u00ae<\/sup>, YESCARTA<sup>\u00ae<\/sup> and ZYDELIG<sup>\u00ae<\/sup>.\n<\/p>\n<p class=\"bwalignc\">\nThis report also refers to trademarks, service marks and trade names of other companies.\n<\/p>\n<p class=\"bwalignc\"><i>For more information on Gilead Sciences, Inc., please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.gilead.com%2F&amp;esheet=52359306&amp;newsitemid=20210111005378&amp;lan=en-US&amp;anchor=www.gilead.com&amp;index=2&amp;md5=945a654c5ccb7142e8bf2615aa839fb2\">www.gilead.com <\/a>or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).<\/i><\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwpadl0\" colspan=\"3\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\"><b>GILEAD SCIENCES, INC.<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0\" colspan=\"3\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\"><b>RECONCILIATION OF GAAP TO NON-GAAP 2020 FULL YEAR GUIDANCE<sup>(1)(2)<\/sup><\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0\" colspan=\"3\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\"><b>(unaudited)<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwpadl0 bwvertalignb\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><b>(in millions, except percentages and per share amounts)<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwalignc\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\"><b>Previously Updated<br \/>\n<br \/>October 28, 2020<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwalignc\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\"><b>Updated<br \/>\n<br \/>January 11, 2021<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Projected product gross margin GAAP to non-GAAP reconciliation:<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwpadl0 bwalignc\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwpadl0 bwalignc\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwrowaltcolor0 bwpadl0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nGAAP projected product gross margin\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwrowaltcolor0 bwpadl0 bwalignc\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n81% &#8211; 82%\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwrowaltcolor0 bwpadl0 bwalignc\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n~ 81.5%\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl3\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nAcquisition-related expenses\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignc\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n5%\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignc\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n5.0%\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwrowaltcolor0 bwpadl0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nNon-GAAP projected product gross margin\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwdoublebottom bwrowaltcolor0 bwpadl0 bwalignc\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n86% &#8211; 87%\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwdoublebottom bwrowaltcolor0 bwpadl0 bwalignc\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n~ 86.5%\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Projected operating income GAAP to non-GAAP reconciliation:<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwpadl0 bwalignc\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwpadl0 bwalignc\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwrowaltcolor0 bwpadl0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nGAAP projected operating income\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwrowaltcolor0 bwpadl0 bwalignc\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n$2,200 &#8211; $2,700\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwrowaltcolor0 bwpadl0 bwalignc\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n$4,050 &#8211; $4,150\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl3\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nAcquisition-related and acquired IPR&amp;D expenses\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignc\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n8,500\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignc\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n7,600\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwrowaltcolor0 bwpadl0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nNon-GAAP projected operating income\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwrowaltcolor0 bwpadl0 bwalignc bwdoublebottom\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n$10,700 &#8211; $11,200\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwrowaltcolor0 bwpadl0 bwalignc bwdoublebottom\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n$11,650 &#8211; $11,750\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nGAAP projected effective tax rate\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwalignc\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n~110%\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwalignc\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n~102.0% &#8211; 102.5%\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwrowaltcolor0\" rowspan=\"1\" colspan=\"1\"><b>Projected effective tax rate GAAP to non-GAAP reconciliation:<\/b><\/td>\n<td class=\"bwpadl0 bwrowaltcolor0 bwalignc\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwrowaltcolor0 bwalignc\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nAmortization of deferred tax assets and tax rate effects of adjustments noted\n<\/p>\n<p class=\"bwcellpmargin\">\nabove\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwalignc bwsinglebottom\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n(90)%\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwalignc bwsinglebottom\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n(83.0)%\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwrowaltcolor0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nNon-GAAP projected effective tax rate\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwrowaltcolor0 bwalignc bwdoublebottom\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n~ 20%\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwrowaltcolor0 bwalignc bwdoublebottom\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n~ 19.0% &#8211; 19.5%\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Projected diluted EPS GAAP to non-GAAP reconciliation:<\/b><\/p>\n<\/td>\n<td class=\"bwpadl0 bwalignc\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n$(0.25) &#8211; $0.10\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwalignc\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n$(0.08) &#8211; $0.02\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwrowaltcolor0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nGAAP projected diluted EPS (loss per share)\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwrowaltcolor0 bwalignc\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwrowaltcolor0 bwalignc\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3 bwvertalignb\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nAcquisition-related, acquired IPR&amp;D expenses, amortization of deferred tax<br \/>\n<br \/>assets and historical fair value adjustments of equity securities\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwalignc bwsinglebottom\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n6.50\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwalignc bwsinglebottom\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n7.06\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwrowaltcolor0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nNon-GAAP projected diluted EPS\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwrowaltcolor0 bwalignc bwdoublebottom\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n$6.25 &#8211; $6.60\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwrowaltcolor0 bwalignc bwdoublebottom\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n$6.98 &#8211; $7.08\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwpadl0\" colspan=\"3\" rowspan=\"1\">_______________<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadr0 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><sup>(1)<\/sup><\/p>\n<\/td>\n<td rowspan=\"1\" colspan=\"1\" \/>\n<td class=\"bwvertalignt bwpadl0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nStarting in 2020, Gilead no longer regularly excludes stock-based compensation expense from its non-GAAP financial information.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadr0 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><sup>(2)<\/sup><\/p>\n<p class=\"bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td rowspan=\"1\" colspan=\"1\" \/>\n<td class=\"bwvertalignt bwpadl0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nThe updated 2020 guidance non-GAAP financial information excludes acquisition-related expenses including amortization, acquired IPR&amp;D expenses including the initial costs of externally developed IPR&amp;D with no alternative future use, upfront collaboration and licensing expenses and IPR&amp;D impairments, and other items that are considered unusual or not representative of underlying trends of Gilead\u2019s business, fair value adjustments of equity securities and discrete and related tax charges or benefits associated with changes in tax related laws and guidelines.\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\n\u00a0\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210111005378r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210111005378\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210111005378\/en\/<\/a><\/span><\/p>\n<p><b><span class=\"bwuline\">Investors<br \/>\n<\/span><\/b><br \/><b>Monica Tellado<br \/>\n<\/b><br \/><b>(650) 574-3000<br \/>\n<br \/><\/b><br \/><b><span class=\"bwuline\">Media<br \/>\n<\/span><\/b><br \/><b>Amy Flood<br \/>\n<\/b><br \/><b>(650) 522-5643<\/b><\/p>\n<p><b>KEYWORDS:<\/b> United States North America California<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Hospitals Pharmaceutical Health<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20210111005378\/en\/778437\/3\/GCP_Primarylarge_%281%29.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Gilead Sciences Announces Updated 2020 Guidance FOSTER CITY, Calif.&#8211;(BUSINESS WIRE)&#8211; Gilead Sciences, Inc. (Nasdaq: GILD) today announced the company has revised certain elements of its full year 2020 guidance. Updated Full Year 2020 Guidance (In millions, except percentages and per share amounts) Previously Updated October 28, 2020 Updated January 11, 2021 Product Sales $23,000 &#8211; $23,500 $24,300 &#8211; $24,350 Product Sales excluding Veklury \u00a0 $21,500 &#8211; $21,525 Veklury \u00a0 $2,800 &#8211; $2,825 Non-GAAP \u00a0 \u00a0 Product Gross Margin 86% &#8211; 87% ~ 86.5% R&amp;D Expenses Mid-teens percentage growth \u00a0 ~ 20% growth SG&amp;A Expenses Low double-digit percentage growth \u00a0 ~ 10% growth Operating Income $10,700 &#8211; $11,200 $11,650 &#8211; $11,750 Effective Tax Rate ~ 20% ~ 19.0% &#8211; 19.5% Diluted &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-sciences-announces-updated-2020-guidance\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Gilead Sciences Announces Updated 2020 Guidance&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-411612","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Gilead Sciences Announces Updated 2020 Guidance - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-sciences-announces-updated-2020-guidance\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gilead Sciences Announces Updated 2020 Guidance - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Gilead Sciences Announces Updated 2020 Guidance FOSTER CITY, Calif.&#8211;(BUSINESS WIRE)&#8211; Gilead Sciences, Inc. (Nasdaq: GILD) today announced the company has revised certain elements of its full year 2020 guidance. Updated Full Year 2020 Guidance (In millions, except percentages and per share amounts) Previously Updated October 28, 2020 Updated January 11, 2021 Product Sales $23,000 &#8211; $23,500 $24,300 &#8211; $24,350 Product Sales excluding Veklury \u00a0 $21,500 &#8211; $21,525 Veklury \u00a0 $2,800 &#8211; $2,825 Non-GAAP \u00a0 \u00a0 Product Gross Margin 86% &#8211; 87% ~ 86.5% R&amp;D Expenses Mid-teens percentage growth \u00a0 ~ 20% growth SG&amp;A Expenses Low double-digit percentage growth \u00a0 ~ 10% growth Operating Income $10,700 &#8211; $11,200 $11,650 &#8211; $11,750 Effective Tax Rate ~ 20% ~ 19.0% &#8211; 19.5% Diluted &hellip; Continue reading &quot;Gilead Sciences Announces Updated 2020 Guidance&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-sciences-announces-updated-2020-guidance\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-11T11:03:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210111005378r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"10 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gilead-sciences-announces-updated-2020-guidance\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gilead-sciences-announces-updated-2020-guidance\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Gilead Sciences Announces Updated 2020 Guidance\",\"datePublished\":\"2021-01-11T11:03:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gilead-sciences-announces-updated-2020-guidance\\\/\"},\"wordCount\":1912,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gilead-sciences-announces-updated-2020-guidance\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210111005378r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gilead-sciences-announces-updated-2020-guidance\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gilead-sciences-announces-updated-2020-guidance\\\/\",\"name\":\"Gilead Sciences Announces Updated 2020 Guidance - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gilead-sciences-announces-updated-2020-guidance\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gilead-sciences-announces-updated-2020-guidance\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210111005378r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-01-11T11:03:44+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gilead-sciences-announces-updated-2020-guidance\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gilead-sciences-announces-updated-2020-guidance\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gilead-sciences-announces-updated-2020-guidance\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210111005378r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210111005378r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gilead-sciences-announces-updated-2020-guidance\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gilead Sciences Announces Updated 2020 Guidance\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Gilead Sciences Announces Updated 2020 Guidance - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-sciences-announces-updated-2020-guidance\/","og_locale":"en_US","og_type":"article","og_title":"Gilead Sciences Announces Updated 2020 Guidance - Market Newsdesk","og_description":"Gilead Sciences Announces Updated 2020 Guidance FOSTER CITY, Calif.&#8211;(BUSINESS WIRE)&#8211; Gilead Sciences, Inc. (Nasdaq: GILD) today announced the company has revised certain elements of its full year 2020 guidance. Updated Full Year 2020 Guidance (In millions, except percentages and per share amounts) Previously Updated October 28, 2020 Updated January 11, 2021 Product Sales $23,000 &#8211; $23,500 $24,300 &#8211; $24,350 Product Sales excluding Veklury \u00a0 $21,500 &#8211; $21,525 Veklury \u00a0 $2,800 &#8211; $2,825 Non-GAAP \u00a0 \u00a0 Product Gross Margin 86% &#8211; 87% ~ 86.5% R&amp;D Expenses Mid-teens percentage growth \u00a0 ~ 20% growth SG&amp;A Expenses Low double-digit percentage growth \u00a0 ~ 10% growth Operating Income $10,700 &#8211; $11,200 $11,650 &#8211; $11,750 Effective Tax Rate ~ 20% ~ 19.0% &#8211; 19.5% Diluted &hellip; Continue reading \"Gilead Sciences Announces Updated 2020 Guidance\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-sciences-announces-updated-2020-guidance\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-11T11:03:44+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210111005378r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-sciences-announces-updated-2020-guidance\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-sciences-announces-updated-2020-guidance\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Gilead Sciences Announces Updated 2020 Guidance","datePublished":"2021-01-11T11:03:44+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-sciences-announces-updated-2020-guidance\/"},"wordCount":1912,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-sciences-announces-updated-2020-guidance\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210111005378r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-sciences-announces-updated-2020-guidance\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-sciences-announces-updated-2020-guidance\/","name":"Gilead Sciences Announces Updated 2020 Guidance - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-sciences-announces-updated-2020-guidance\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-sciences-announces-updated-2020-guidance\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210111005378r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-01-11T11:03:44+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-sciences-announces-updated-2020-guidance\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/gilead-sciences-announces-updated-2020-guidance\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-sciences-announces-updated-2020-guidance\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210111005378r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210111005378r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-sciences-announces-updated-2020-guidance\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Gilead Sciences Announces Updated 2020 Guidance"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/411612","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=411612"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/411612\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=411612"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=411612"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=411612"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}